Skip to content

Diabetic neuropathic pain

TL;DR — Painful diabetic neuropathy is usually length-dependent distal symmetric polyneuropathy, but pain may precede routine nerve-conduction abnormalities. Pain affects about 10–20% of people with diabetes and 40–50% of those with diabetic neuropathy in older synthesis (Veves 2008, PMID 18828198). Type 1 diabetes responds more clearly to intensive glycemic prevention than type 2 disease (Peltier 2014, PMID 24803311). OPTION-DM found similar first-line pathways and greater reduction with combination rescue (Tesfaye 2022, PMID 36007534).

Phenotype

Typical disease starts in toes and ascends symmetrically with burning, shocks, allodynia and/or numbness (Feldman 2019, PMID 31197153). Rapid, asymmetric, motor-predominant or non-length-dependent disease requires another-cause workup (Jensen 2021, PMID 33711103).

Pain versus loss

The same structural neuropathy can be painful or painless; pain intensity does not measure ulcer risk (Calcutt 2020, PMID 32999525). Protective sensation, pulses, skin and footwear require separate assessment.

Mechanisms

Hyperglycemia, dyslipidemia, mitochondrial stress, oxidative injury and microvascular dysfunction converge on axons, Schwann cells and DRG neurons (Feldman 2019, PMID 31197153).

The pain phenotype is not simply a more severe version of axonal loss. Surviving nociceptors may become hyperexcitable while distal terminals degenerate; altered sodium-channel expression, ectopic discharge, neuroimmune signaling and impaired descending inhibition can coexist with numbness (Calcutt 2020, PMID 32999525). A meta-analysis of 13 cross-sectional, case-control and cohort studies found higher inflammatory mediators in painful than painless diabetic neuropathy, but the designs do not establish whether inflammation causes pain or follows tissue injury (Baka 2021, PMID 34389235).

Sex is a plausible effect modifier, yet animal and human findings are not interchangeable. A focused review found sex-dependent molecular mechanisms in preclinical models and clinical differences in presentation, while emphasizing that neither literature yet yields a treatment-selection rule (Merlin 2024, PMID 39682771).

A targeted PubMed search on 2026-08-30 found sex-specific preclinical pharmacology and association studies but no randomized human treatment-by-sex validation. The current gap is therefore a missing predictive interaction and replication standard, not a lack of biological sex-difference research.

Mechanistic layer Candidate process Clinical implication Evidentiary limit
Metabolic Hyperglycemia, dyslipidemia, oxidative stress Prevention requires cardiometabolic management Established pain may persist after metabolic improvement
Axonal Distal terminal loss and ectopic firing Pain and sensory loss can coexist Nerve-conduction amplitude does not quantify pain
Immune Cytokine and neuroimmune activation Candidate stratification/target pathway Mostly associative human data
Central Amplification and impaired inhibition Supports multidimensional phenotyping Does not erase the peripheral lesion
Sex-related Different immune/neural signaling by sex Prespecify sex interactions in trials No validated sex-specific algorithm

Diagnosis

Diabetes plus foot pain is insufficient. Map signs, confirm large-fiber disease when indicated, and consider skin biopsy for selected small-fiber presentations (Rosenberger 2020, PMID 32036431).

Disease modification

Intensive glycemic control prevents neuropathy more consistently in type 1 than type 2 diabetes; established pain is not reliably reversed (Peltier 2014, PMID 24803311). Cardiometabolic risk remains relevant (Feldman 2019, PMID 31197153).

Lifetime diabetic peripheral neuropathy prevalence exceeds 50% in some syntheses, whereas painful neuropathy affects approximately 15–25% of people with diabetes; denominator, diabetes type, duration and ascertainment explain part of the range (Jang 2023, PMID 37670573). These figures should not be used as an individual prognosis.

No drug has established disease-modifying efficacy for painful diabetic neuropathy. Current pharmacologic and topical therapies are symptom-directed; glucose control, blood-pressure and lipid management, smoking cessation and foot protection address progression and complications rather than reliably reversing pain (Jang 2023, PMID 37670573). Device studies now report sensory and structural signals, but those signals require prospective mechanistic validation before they establish disease modification.

Drug evidence

Duloxetine 60 mg produced ≥50% relief RR 1.73 and NNT 5 (95% CI 4–7) at 12 weeks (Lunn 2014, PMID 24385423). NeuPSIG pooled NNTs were 7.2 for gabapentin and 7.7 for pregabalin (Finnerup 2015, PMID 25575710).

Comparative interpretation is constrained by different responder thresholds, durations and enrichment rules. The AAN update recommends offering medication from effective classes and switching class when benefit is inadequate or harms predominate; it also advises against opioids for painful diabetic polyneuropathy (Price 2022, PMID 34965987). Reviews place gabapentinoids and duloxetine among first-line choices, while describing tapentadol and capsaicin 8% as later options with modest average effects (D'Souza 2022, PMID 35716275).

Option Best quantified signal Main trade-off Interpretation
Duloxetine NNT 5 (95% CI 4–7) for ≥50% relief at 12 weeks Nausea, blood pressure, withdrawal Condition-specific evidence; short duration
Pregabalin NeuPSIG pooled NNT 7.7 Dizziness, edema, renal accumulation Pooled neuropathic conditions
Gabapentin NeuPSIG pooled NNT 7.2 Sedation, titration burden, renal accumulation Pooled neuropathic conditions
TCA Class efficacy in guidelines Anticholinergic, orthostatic and cardiac harm Often limited by age/comorbidity
Capsaicin 8% Modest benefit in selected localized pain Application pain, repeated procedures Does not restore sensation
Opioids Short-term analgesic signal Dependence, overdose, tolerance AAN advises against routine use

Combination evidence

OPTION-DM pain fell from mean 6.6 to 3.3 across three 16-week pathways; between-pathway differences were 0.0–0.1 with confidence intervals crossing zero (Tesfaye 2022, PMID 36007534). COMBO-DN combination versus high-dose monotherapy changed pain −2.35 versus −2.16 (P=0.370) (Tesfaye 2013, PMID 23732189).

Device evidence

Selected refractory patients had superior six-month response with 10-kHz SCS plus conventional care, but procedure risk and durability limit generalization (Petersen 2021, PMID 33818600).

The pivotal trial recruited people with refractory symptoms and does not establish first-line effectiveness, comparative value against optimized combination pharmacotherapy, or lifetime device durability. Infection, lead problems, revision and explant belong in the same endpoint frame as pain response. Evidence reviews regard both 10-kHz and tonic SCS as supported for refractory disease, but selection remains procedural and phenotype-dependent (D'Souza 2022, PMID 35716275).

Function and burden

In a six-country cross-sectional sample of 140 people with painful diabetic neuropathy, mean pain severity was 5.0/10; 57% reported moderate and 25% severe pain, 35% reported employment disruption, and 91% were using prescription treatment (Tölle 2006, PMID 16389164). Because recruitment occurred in care settings, these are burden estimates among treated patients, not population prevalence.

Pain outcomes should therefore be paired with sleep, walking, participation and medication burden. Foot-safety outcomes must be analyzed separately: analgesia can improve sleep or walking while numbness and ulcer risk persist.

Clinical matrix

Task Minimum dataset
Diagnose Distribution, signs, competing causes
Protect foot Skin, pulses, monofilament, footwear
Choose drug Comorbidity, renal function, falls risk
Judge response Pain, sleep, function, adverse effects
Escalate Adequate dose/duration/adherence
Consider device Refractory status and procedural risk

Evidence interpretation map

The table makes the evidence role and inferential boundary explicit; it is not a replacement for the full reports.

PMID Year Evidence role What it cannot establish alone
31197153 2019 Broad disease-primer synthesis Individual prognosis or treatment response
34389235 2021 Inflammatory-biomarker meta-analysis Causal immune mechanism
36007534 2022 Head-to-head crossover pathways Benefit beyond 16 weeks
33818600 2021 Randomized 10-kHz SCS comparison First-line or lifetime device effectiveness
16389164 2006 Cross-sectional burden study Population prevalence or causal impact

Minimum reporting controls

Domain Required report
Case definition Possible, probable or definite neuropathic pain
Etiology Lesion/disease and diagnostic evidence
Distribution Focal, length-dependent, dermatomal, at-level or below-level
Baseline phenotype Negative and positive sensory signs
Comparator Placebo/sham, active care or natural history
Exposure Dose, duration, adherence and co-interventions
Benefit Mean change plus ≥30% and ≥50% responders where applicable
Function Sleep, mobility, participation and patient global change
Harm Adverse events, withdrawals and serious events
Durability Follow-up after treatment and attrition
Subgroups Prespecified interaction test, not within-group significance
Missingness Denominator and imputation method

Reporting cautions

  • Do not infer lesion presence from a symptom descriptor.
  • Do not convert a group-average association into an individual diagnostic rule.
  • Do not treat statistical significance as clinically important benefit.
  • Do not compare NNTs without checking outcome threshold, duration and population.
  • Do not interpret an inactive or completed registry record as proof of efficacy.
  • Do not merge painful and painless neuropathy outcomes.
  • Do not omit adverse-event withdrawals from responder interpretation.
  • Do not call a post hoc subgroup predictive without an interaction test.
  • Do not generalize a focal peripheral result to central neuropathic pain.
  • State when evidence is short-term, indirect or restricted to a selected cohort.

Open questions

  • OQ-1: Can metabolic intervention reverse established painful disease?
  • OQ-2: Which phenotype predicts painful versus painless loss?
  • OQ-3: What sequence best balances benefit and falls?
  • OQ-4: Does combination benefit persist beyond 16 weeks?

References

  1. Veves A, Backonja M, Malik RA. Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options. Pain Med. 2008;9:660-74. PMID 18828198
  2. Peltier A, Goutman SA, Callaghan BC. Painful diabetic neuropathy. BMJ. 2014;348:g1799. PMID 24803311
  3. Feldman EL, Callaghan BC, Pop-Busui R, et al.. Diabetic neuropathy. Nat Rev Dis Primers. 2019;5:41. PMID 31197153
  4. Jensen TS, Karlsson P, Gylfadottir SS, et al.. Painful and non-painful diabetic neuropathy, diagnostic challenges and implications for future management. Brain. 2021;144:1632-1645. PMID 33711103
  5. Calcutt NA. Diabetic neuropathy and neuropathic pain: a (con)fusion of pathogenic mechanisms? Pain. 2020;161:S65-S86. PMID 32999525
  6. Rosenberger DC, Blechschmidt V, Timmerman H, et al.. Challenges of neuropathic pain: focus on diabetic neuropathy. J Neural Transm (Vienna). 2020;127:589-624. PMID 32036431
  7. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014;2014:CD007115. PMID 24385423
  8. Finnerup NB, Attal N, Haroutounian S, et al.. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162-73. PMID 25575710
  9. Wiffen PJ, Derry S, Bell RF, et al.. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6:CD007938. PMID 28597471
  10. Derry S, Bell RF, Straube S, et al.. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019;1:CD007076. PMID 30673120
  11. Tesfaye S, Sloan G, Petrie J, et al.. Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial. Lancet. 2022;400:680-690. PMID 36007534
  12. Tesfaye S, Wilhelm S, Lledo A, et al.. Duloxetine and pregabalin: high-dose monotherapy or their combination? The "COMBO-DN study"--a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain. 2013;154:2616-2625. PMID 23732189
  13. Saul H, Deeney B, Imison C, et al.. Combination therapy for painful diabetic neuropathy is safe and effective. BMJ. 2023;381:866. PMID 37085164
  14. Petersen EA, Stauss TG, Scowcroft JA, et al.. Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy: A Randomized Clinical Trial. JAMA Neurol. 2021;78:687-698. PMID 33818600
  15. Petersen EA. Spinal cord stimulation in painful diabetic neuropathy: An overview. Diabetes Res Clin Pract. 2023;206 Suppl 1:110760. PMID 38245324
  16. Price R, Smith D, Franklin G, et al.. Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary: Report of the AAN Guideline Subcommittee. Neurology. 2022;98:31-43. PMID 34965987
  17. Sloan G, Alam U, Selvarajah D, et al.. The Treatment of Painful Diabetic Neuropathy. Curr Diabetes Rev. 2022;18:e070721194556. PMID 34238163
  18. Zakin E, Abrams R, Simpson DM. Diabetic Neuropathy. Semin Neurol. 2019;39:560-569. PMID 31639839
  19. Russell JW, Zilliox LA. Diabetic neuropathies. Continuum (Minneap Minn). 2014;20:1226-40. PMID 25299279
  20. Lee-Kubli CA, Calcutt NA. Painful neuropathy: Mechanisms. Handb Clin Neurol. 2014;126:533-57. PMID 25410243
  21. Strand N, Wie C, Peck J, et al.. Small Fiber Neuropathy. Curr Pain Headache Rep. 2022;26:429-438. PMID 35384587
  22. Lauria G, Hsieh ST, Johansson O, et al.. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol. 2010;17:903-12, e44-9. PMID 20642627
  23. Sayed D, Deer TR, Hagedorn JM, et al.. A Systematic Guideline by the ASPN Workgroup on the Evidence, Education, and Treatment Algorithm for Painful Diabetic Neuropathy: SWEET. J Pain Res. 2024;17:1461-1501. PMID 38633823
  24. Lazzarini PA, Jarl G, Gooday C, et al.. Effectiveness of offloading interventions to heal foot ulcers in persons with diabetes: a systematic review. Diabetes Metab Res Rev. 2020;36 Suppl 1:e3275. PMID 32176438
  25. Benbow SJ, Cossins L, MacFarlane IA. Painful diabetic neuropathy. Diabet Med. 1999;16:632-44. PMID 10477207
  26. D'Souza RS, Barman R, Joseph A, et al. Evidence-Based Treatment of Painful Diabetic Neuropathy: a Systematic Review. Curr Pain Headache Rep. 2022;26:583-594. PMID 35716275
  27. Baka P, Escolano-Lozano F, Birklein F. Systemic inflammatory biomarkers in painful diabetic neuropathy. J Diabetes Complications. 2021;35:108017. PMID 34389235
  28. Merlin E, Salio C, Ferrini F. Painful Diabetic Neuropathy: Sex-Specific Mechanisms and Differences from Animal Models to Clinical Outcomes. Cells. 2024;13. PMID 39682771
  29. Jang HN, Oh TJ. Pharmacological and Nonpharmacological Treatments for Painful Diabetic Peripheral Neuropathy. Diabetes Metab J. 2023;47:743-756. PMID 37670573
  30. Tölle T, Xu X, Sadosky AB. Painful diabetic neuropathy: a cross-sectional survey of health state impairment and treatment patterns. J Diabetes Complications. 2006;20:26-33. PMID 16389164